Today Ipsen and Forseen announced an exclusive global licensing agreement for FS001 an antibody drug conjugate ( ADC) with first-in-class potential. FS001 targets an antigen that is tumor-associated that is overexpressed in many solid tumours and plays a critical role in tumor metastasis and proliferation. Identification of this novel tumour antigen can be done by Foreseen’s AI-powered high throughput and screening platforms. AI-powered screening platforms are used to analyse their vast collection of well-characterized clinical tumour samples. FS001 used an innovative, stable and cleavage linker coupled to a potent topoisomerase I inhibitor. In preclinical trials, FS001 has shown efficacy in multi-drug resistant cancer models. The agreement gives exclusive rights to develop. Comercialize and manufacture FS001.
Mary Jane Hinrichs, SVP and head of Early Development at Ipsen, said they are excited to add FS001, the second ADC Ipsen that has been in-licensed to their grown pipeline this year. Using cutting-edge proteomics technology and AI-powered screening platforms the Forseen team has uncovered a noble and clinically relevant target that could unlock the potential of Antibody Drug Conjugates (ADC) for people living with non-treatable cancer. As they are preparing for the initiation of a Phase-1 clinical trial, they will evaluate FS001 in a selected solid type of tumour, which they hope will treat people living with cancer around the world.
FS001 is a potential first-in-class ADC that demonstrated efficient pre-clinically in multiple solid tumours and a favourable safety profile with a wide therapeutic window in animal studies.
“Our partnership with Ipsen provides a strong endorsement to our high throughout integral translation proteomics platform approach to discover and develop innovative and therapeutic products with first-in-class potential”, said Catherine Wong, Founder and Chairman of Forseen.
Foreseen Biotechnology is eligible to get up to $ 1.03 billion. Under the terms of the agreement, Ipsen will have responsibility for Phase I preparation activities that include submission of the Investigational New Drug (IND) application, and all subsequent clinical development, manufacturing and global activities.
Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas. Ipsen is fueled by external innovation and supported by nearly 100 years of development experience and a global hub in the U.S., France and the UK. Ipsen has teams in more than 40 countries and their partnership around the world enables us to bring medicines to patients in more than 80 countries.
ADCs have three components: the antibody, a payload and a linker. This antibody selectively targets an identified tumour antigen. Payloads are the pharmaceutically active component to treat the cancer, attached to the antibody via a chemical linker. The linker connects antibodies and the payloads and reduces the amount of payload that reaches non-tumour tissues.
For more such news check https://factspharmacy.com
